Skip to content
Catalyst

PapersPMID:34818350

Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.

PloS one2021The record ↗

  1. Finding, moderate evidencelowersDiastolic blood pressure

What moved

1 findingHow to read these marks →
  • “The patients treated with rosuvastatin in addition to antihypertensives had a significantly lower DBP (MD = −2.12 mmHg; 95% CI = −3.72 to −0.52; Pfixed-effects model = 0.009; I 2 = 0%, Pheterogeneity = 0.97) than the patients treated with antihypertensives alone.”
    Study
    meta-analysis
    Duration
    8 weeks
    Effect
    −2.12 mean difference, 95% CI −3.72 to −0.52
    Dose studied
    rosuvastatin 20 mg/day
    Population
    Patients with hypertension and dyslipidemia treated with rosuvastatin 20 mg/day plus antihypertensive agents (an ARB, or an ARB plus a calcium channel blocker), compared with the same antihypertensive background alone

Study record

Design
meta-analysis
Species
human
Population
Adult patients with hypertension and dyslipidemia treated with rosuvastatin 20 mg/day plus antihypertensive agents versus antihypertensive agents alone
Participants
507
Comparator
not stated in the paper / placebo
Duration
56 days
Endpoints measured
4